Ovid Therapeutics Inc (NASDAQ: OVID) on Monday, soared 4.62% from the previous trading day, before settling in for the closing price of $1.30. Within the past 52 weeks, OVID’s price has moved between $0.68 and $4.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 275.67%. The company achieved an average annual earnings per share of 33.01%. With a float of $58.43 million, this company’s outstanding shares have now reached $70.69 million.
Let’s determine the extent of company efficiency that accounts for 40 employees. In terms of profitability, gross margin is 19161.0%, operating margin of -12008.3%, and the pretax margin is -5241.52%.
Ovid Therapeutics Inc (OVID) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ovid Therapeutics Inc is 17.66%, while institutional ownership is 54.87%. The most recent insider transaction that took place on Mar 18 ’24, was worth 50,364. In this transaction CEO of this company bought 18,248 shares at a rate of $2.76, taking the stock ownership to the 3,616,715 shares.
Ovid Therapeutics Inc (OVID) Recent Fiscal highlights
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.16 earnings per share (EPS) for the period topping the consensus outlook (set at -0.19) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.01% per share during the next fiscal year.
Ovid Therapeutics Inc (NASDAQ: OVID) Trading Performance Indicators
Ovid Therapeutics Inc (OVID) is currently performing well based on its current performance indicators. A quick ratio of 5.73 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 169.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.71 in one year’s time.
Technical Analysis of Ovid Therapeutics Inc (OVID)
Looking closely at Ovid Therapeutics Inc (NASDAQ: OVID), its last 5-days average volume was 0.38 million, which is a drop from its year-to-date volume of 0.39 million. As of the previous 9 days, the stock’s Stochastic %D was 72.81%. Additionally, its Average True Range was 0.09.
During the past 100 days, Ovid Therapeutics Inc’s (OVID) raw stochastic average was set at 86.08%, which indicates a significant increase from 70.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.89% in the past 14 days, which was lower than the 75.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1572, while its 200-day Moving Average is $2.1167. However, in the short run, Ovid Therapeutics Inc’s stock first resistance to watch stands at $1.4500. Second resistance stands at $1.5400. The third major resistance level sits at $1.6100. If the price goes on to break the first support level at $1.2900, it is likely to go to the next support level at $1.2200. Now, if the price goes above the second support level, the third support stands at $1.1300.
Ovid Therapeutics Inc (NASDAQ: OVID) Key Stats
Market capitalization of the company is 96.52 million based on 70,972K outstanding shares. Right now, sales total 390 K and income totals -52,340 K. The company made 170 K in profit during its latest quarter, and 8,520 K in sales during its previous quarter.
